BiotechTube
Ageless Biotech

Ageless Biotech

San Francisco, United States· Est.
agelessbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Ageless Biotech is a private, pre-revenue company founded in 2019 and based in San Francisco, operating in the cell and gene therapy sector. Its core technology involves proprietary processing of adipose (fat) and 'discardable' afterbirth tissues to create potent biologic products aimed at treating all forms of osteoarthritis through intra-articular injection. The company is on the cusp of initiating a Phase 2b clinical trial, leveraging a team with extensive FDA regulatory and clinical development experience to advance its pipeline.

Osteoarthritis

Technology Platform

Proprietary processing of adipose-derived Stromal Vascular Fraction (SVF) and minimally manipulated fetal/afterbirth tissues to create potent biologic mixtures containing stem cells, stromal cells, exosomes, and signaling molecules for regenerative applications.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global osteoarthritis treatment market represents a multi-billion dollar opportunity with high unmet need for disease-modifying therapies.
The company's use of ethically non-controversial, discardable tissue sources could facilitate broader regulatory and market acceptance compared to other cell therapies.

Risk Factors

High clinical trial risk as the company approaches a pivotal Phase 2b study.
Significant funding risk as a private, pre-revenue company needing capital for expensive trials.
Competitive and regulatory risks are substantial in the evolving cell therapy space for orthopedics.

Competitive Landscape

The field of regenerative medicine for osteoarthritis is competitive, with numerous biotechs exploring mesenchymal stem cells (MSCs) from bone marrow, adipose, and other sources, as well as gene therapies and other biologics. Ageless Biotech differentiates through its specific tissue sources and proprietary processing technology, but must demonstrate superior efficacy or safety in clinical trials.

More companies in Cell & Gene Therapy →More companies in United States →